In order to break even, they need to increase the cost of a course of treatment by about ~$28k/patient.
The new price doubles the price to about ~$50k/patient, which is still short of this number (but bleeding $3k*45 patients = $135k/year is much more manageable than bleeding $1M dollars a year).
So even if the drug was priced at $28K/patient, the company would be making zero profit. Huh...
1. "hey, this guy wants to buy this drug that we are producing as a public service but losing money on",
2. "oh shit - he raised the price to an astronomical figure and now we all look bad. oops",
3. "we're getting the rights back before this turns into a giant PR nightmare. while we're at it, let's raise the price to a sustainable level."
The article doesn't make it sound like there was any malice on Purdue's part.